Phase III Long-Term Clinical Study of CSG452(RG7201) in Patients with Type 2 Diabetes. -Long-term Study in Monotherapy
Latest Information Update: 23 Jul 2021
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical; Kowa; Sanofi K.K.
- 01 Jul 2021 Results of post hoc analysis (n=157) evaluating impact of long-term administration and subsequent discontinuation of the SGLT2 inhibitor tofogliflozin on estimated plasma volume (ePV), brain natriuretic peptide and the relationship between changes in ePV, BNP and body weight, published in the Diabetes, Obesity and Metabolism
- 29 Jun 2021 Results (n=774) assessing predictors of Hb after short- and long-term therapy with tofogliflozin (TOFO), a SGLT2i, and explored its impact on Hb in relation to anemia and polycythemia in type 2 diabetes mellitus (T2DM) presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 16 Jun 2020 Results of pooled analysis assessing the impact of SGLT2is on plasma volume and beta-hydroxybutyrate according to cardiac workload, presented at the 80th Annual Scientific Sessions of the American Diabetes Association